About the Study

Prevention of relapse in patients with schizophrenia.

The primary objective of the study is to evaluate the efficacy and safety of Lumateperone relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. This study is sponsored by Intra-Cellular Therapies, Inc.

Length of Study:  2 – 4 weeks inpatient, with up to 47 weeks outpatient visits.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18 – 60 years old
• have been diagnosed with schizophrenia
• are willing to spend 2 – 4 weeks in our 24-hr observation unit

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.